A nationwide 12-month observatory of automated insulin delivery shows improved glucose control, sustained adoption, and reduced acute severe events.

ABSTRACT:

Aims

A nationwide observational study was conducted to assess the 12-month effectiveness of AID systems in the routine care of people with Type 1 diabetes (PwT1D).

Methods

All PwT1D, adults, and children, who initiated AID between January 1, 2022, and December 31, 2022, were included across 79 centres. Clinical data, continuous glucose monitoring (CGM) parameters, acute severe events in the last year, and HbA1c levels were collected at AID initiation, and after 3, 6, and 12 months of AID treatment. Median values [interquartile range, IQR] and % PwT1D with acute severe events were reported. The primary outcome was the change in time in range (TIR; 3.9-10 mmol/L) after 1 year with AID.

Results

A total of 2741 PwT1D were included: 44.4% male, age 38 years [29], BMI 24.5 

SUBMITTER: Riveline JP 

PROVIDER: S-EPMC12803582 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature